Plant ID: NPO20715
Plant Latin Name: Astragalus cibarius
Taxonomy Genus: Astragalus
Taxonomy Family: Fabaceae
NCBI TaxonomyDB:
90168
Plant-of-the-World-Online:
n.a.
China
TDP1; PIK3CB; TERT; PIK3CA; GFER; NQO2; PGD; POLB; | |
BCL2; | |
CA12; CA14; CA9; | |
ESR1; | |
PTGS2; | |
KDM4E; | |
DNMT1; | |
FUT7; | |
ABCB1; | |
LMNA; |
Cytochrome P450 Enzymes: | CYP3A4; |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.285E-07 | 7.032E-03 | CA12, CA14, CA9 |
MF | GO:0003824; catalytic activity | GO:0003824; catalytic activity | 7.687E-07 | 7.032E-03 | ABCB1, CA12, CA14, CA9, CYP3A4, DNMT1, FUT7, GFER, KDM4E, NQO2, PGD, PIK3CA, PIK3CB, POLB, PTGS2, TDP1, TERT |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 1.465E-06 | 7.910E-05 | PIK3CA, BCL2, PIK3CB, PTGS2 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 5.763E-07 | 6.224E-05 | CA12, CA9, CA14 |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.021E-05 | 2.758E-04 | PIK3CA, LMNA, BCL2, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 9.016E-06 | 2.758E-04 | DNMT1, ABCB1, PIK3CA, BCL2, PTGS2 |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 2.292E-05 | 4.805E-04 | PIK3CA, PIK3CB, PTGS2 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 2.966E-05 | 4.805E-04 | PIK3CA, PIK3CB, PTGS2 |
09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 3.115E-05 | 4.805E-04 | PIK3CA, BCL2, PIK3CB |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 4.880E-05 | 6.589E-04 | PIK3CA, PIK3CB, ESR1 |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 9.193E-05 | 1.103E-03 | PIK3CA, BCL2, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 1.114E-04 | 1.179E-03 | POLB, TERT, PIK3CA, PIK3CB |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.339E-04 | 1.179E-03 | PIK3CA, BCL2, PIK3CB |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.262E-04 | 1.179E-03 | PIK3CA, PIK3CB, ESR1 |
09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 1.771E-04 | 1.267E-03 | PIK3CA, BCL2, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 1.724E-04 | 1.267E-03 | PIK3CA, PIK3CB, PTGS2 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.419E-04 | 1.179E-03 | PIK3CA, BCL2, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 2.121E-04 | 1.267E-03 | PIK3CA, BCL2, PIK3CB |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.121E-04 | 1.267E-03 | PIK3CA, PIK3CB, ESR1 |
09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 2.229E-04 | 1.267E-03 | PIK3CA, BCL2, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 3.966E-04 | 2.123E-03 | PIK3CA, BCL2, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.758E-04 | 2.591E-03 | PIK3CA, BCL2, PIK3CB, PTGS2 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 2.229E-04 | 1.267E-03 | PIK3CA, BCL2, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 4.996E-04 | 2.346E-03 | PIK3CA, BCL2, PIK3CB |
09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 4.996E-04 | 2.346E-03 | PIK3CA, PIK3CB, PTGS2 |
09150 Organismal Systems | 09153 Circulatory system | hsa04261 | Adrenergic signaling in cardiomyocytes | 4.127E-04 | 2.123E-03 | PIK3CA, BCL2, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.034E-03 | 3.706E-03 | PIK3CA, PIK3CB, ESR1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 1.019E-03 | 3.706E-03 | PIK3CA, BCL2, PIK3CB |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.019E-03 | 3.706E-03 | PIK3CA, BCL2, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.064E-03 | 3.706E-03 | POLB, PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 1.416E-03 | 4.636E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.903E-03 | 5.431E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 9.166E-04 | 3.706E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.223E-03 | 4.126E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 6.885E-04 | 2.974E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.467E-03 | 4.660E-03 | PIK3CA, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 1.624E-03 | 5.012E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 1.845E-03 | 5.431E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 1.042E-03 | 3.706E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 2.080E-03 | 5.480E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.961E-03 | 5.431E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.961E-03 | 5.431E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 2.265E-03 | 5.560E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.020E-03 | 5.455E-03 | PIK3CA, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 4.516E-03 | 8.419E-03 | PIK3CA, BCL2, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 2.393E-03 | 5.618E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 2.393E-03 | 5.618E-03 | PIK3CA, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 3.378E-03 | 7.445E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.263E-03 | 8.371E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04666 | Fc gamma R-mediated phagocytosis | 3.849E-03 | 8.150E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 3.930E-03 | 8.162E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 4.263E-03 | 8.371E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.265E-03 | 5.560E-03 | ABCB1, CYP3A4 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 3.849E-03 | 8.150E-03 | BCL2, PTGS2 |
09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 2.726E-03 | 6.264E-03 | PIK3CA, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04070 | Phosphatidylinositol signaling system | 4.263E-03 | 8.371E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 4.435E-03 | 8.419E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 4.521E-03 | 8.419E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.007E-03 | 6.767E-03 | CYP3A4, PTGS2 |
09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 4.968E-03 | 8.795E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 4.787E-03 | 8.616E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 4.787E-03 | 8.616E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 5.245E-03 | 9.136E-03 | PIK3CA, PIK3CB |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | PIK3CA; PIK3CB; ABCB1; CA9; |
C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1; |
C00-D49: Neoplasms | Melanoma | C43 | TERT; |
NA: NA | Menopausal disorder | NA | ESR1; |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIK3CA; DNMT1; PTGS2; PIK3CB; NQO2; ABCB1; CA9; BCL2; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
NA: NA | Rheumatold arthritis | NA | PTGS2; |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; TERT; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; TERT; BCL2; |
NA: NA | Gonorrheal vaginitis | NA | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | DNMT1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TERT; |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; BCL2; |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
C00-D49: Neoplasms | Liver cancer | C22 | TERT; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DNMT1; PTGS2; ABCB1; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
C00-D49: Neoplasms | Breast cancer | C50 | ESR1; TERT; NQO2; CA9; BCL2; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | DNMT1; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; DNMT1; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; BCL2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT; |
NA: NA | Postmenopausal disorder | NA | ESR1; |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
NA: NA | Joint and muscular pain | NA | PTGS2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2; |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; ABCB1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | BCL2; |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; DNMT1; |
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; BCL2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; ABCB1; |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; |